Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Thrombectomy devices are used to remove blood clots from a main cerebral artery to restore blood flow after acute ischaemic stroke. The devices restore blood flow in people who are not able to have pharmacological treatment. Use of thrombectomy devices can improve long-term neurological outcomes by providing higher rates of procedural recanalization. The device used in medical purpose has a wide range of endovascular tools cleared for removing thrombi from the neurovasculature in acute ischemic stroke patients. In U.S. 3 classes of mechanical thrombectomy devices namely coil retrievers in 2004, aspiration devices in 2008, and stent retrievers in 2012 have been cleared by the food and drug administration. Furthermore, according to centers for disease control and prevention, Stroke kills about 140,000 Americans each year—that’s 1 out of every 20 deaths. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. Likewise, in 2015, stroke deaths accounted for 11.8% of total deaths worldwide, making stroke the second leading global cause of death behind heart disease. Owing to the growth in the number of deaths, the market for thrombectomy devices is expected to propel in near future.
The thrombectomy devices market is segmented by device type, application, end user and geography
The various device types of the thrombectomy devices market are covered in the report such as aspiration thrombectomy devices, mechanical thrombectomy devices, rheolytic thrombectomy devices and ultrasonic thrombectomy devices. Among these, the mechanical thrombectomy devices segment dominated the thrombectomy devices market in 2018, owing to increasing commercialization of this devices in the market.
Based on application, the thrombectomy devices are segmented into cardiovascular, neurovascular and peripheral vascular. The cardiovascular segment dominated the thrombectomy devices market in 2018, owing to the high prevalence rate of cardiovascular disease around the world. Whereas, the peripheral vascular segment is projected to be the fastest growing application segment during the forecast period.
The end user of thrombectomy market are hospitals and surgical centers, ambulatory surgical centers, research laboratories and academic institutes. Among these, the hospitals and surgical centers dominated the thrombectomy market in 2018, due to hospitals and surgical centers are highly preferred by patients over other healthcare centers since they provide advance treatment, diagnosis and surgical intervention for various disorders and also increasing number of hospitals and surgical centers worldwide.
The thrombectomy devices market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. Due to increasing incidence of strokes, advancements in technological and the rising demand for minimally invasive products, the North America region dominated this market in 2018. Whereas, Asia Pacific is expected to witness the fastest growth rate during the forecast period.
The market involves various key companies in the global thrombectomy devices market such as Stryker Corporation, Medtronic PLC, Johnson & Johnson, Terumo Corporation, Boston Scientific Corporation, Spectranetics Corporation, Penumbra, Inc., Argon Medical Devices, Inc., Edwards Lifesciences Corporation, Teleflex Incorporated, Straub Medical AG, BTG International Ltd., Phenox GmbH and Acandis GmbH & Co. Kg. Various strategies, such as expansions, joint ventures, mergers & acquisitions and others have been applied by key manufacturers to gain stronghold of the market.
February 2018, The Food and Drug Administration (FDA) has expanded the indication for Stryker's Trevo Retriever as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset – increasing the treatment window by 18 hours. The expanded indication of Stryker's clot-removal device is in line with the recently updated treatment guidelines from the American Heart Association and American Stroke Association.
March 2017, BTG plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance has been granted to the Ekos Control Unit 4.0. The Ekos system includes an ultrasonic device that uses acoustic pulses, powered by the new Control Unit 4.0, to quickly and safely dissolve blood clots and restore blood flow in patients with pulmonary embolism (PE), deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).
July 2016, Penumbra, Inc., a global interventional therapies company, announced U.S. commercial availability of its most advanced thrombectomy device, the ACE68 Reperfusion Catheter, part of the fully integrated Penumbra System, at the Society of Neuro Interventional Surgery (SNIS) 13th Annual Meeting in Boston, Massachusetts.
June 2015 - Penumbra Inc. announced that the company's ACE64 aspiration thrombectomy system received 510(k) marketing clearance from the U.S. Food and Drug Administration for the revascularization of large vessel occlusions in patients with acute ischemic stroke.
May 2014, Argon Medical Devices, Inc. had launched new product under the brand name LEANERXT Rotational Thrombectomy System as a new addition to the CLEANER family of dialysis products.
The thrombectomy devices market is segmented by device type, application, end user and geography. The various device types of the thrombectomy devices market are covered in the report such as aspiration thrombectomy devices, mechanical thrombectomy devices, rheolytic thrombectomy devices and ultrasonic thrombectomy devices. Among these, the mechanical thrombectomy devices segment dominated the thrombectomy devices market in 2018, owing to increasing commercialization of this devices in the market.
Based on application, the thrombectomy devices are segmented into cardiovascular, neurovascular and peripheral vascular. The cardiovascular segment dominated the thrombectomy devices market in 2018, owing to the high prevalence rate of cardiovascular disease around the world.
The end user of thrombectomy market are hospitals and surgical centers, ambulatory surgical centers, research laboratories and academic institutes. Among these, the hospitals and surgical centers dominated the thrombectomy market in 2018, due to hospitals and surgical centers are highly preferred by patients over other healthcare centers since they provide advance treatment, diagnosis and surgical intervention for various disorders and also increasing number of hospitals and surgical centers worldwide.
The thrombectomy devices market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. Due to increasing incidence of strokes, advancements in technological and the rising demand for minimally invasive products, the North America region dominated this market in 2018.
Why to buy this report:
